Showing results (61-70 of 78) with videos related to
Sort By:
Pageof 8
Clinical and Experimental Rheumatology|April 30, 2014
Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activityN van Herwaarden, S Herfkens-Hol, A van der Maas, et al.Annals of the Rheumatic Diseases|August 22, 2015
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled studyJ T Merrill, R F van Vollenhoven, J P Buyon, et al.Annals of the Rheumatic Diseases|May 8, 2010
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RAJ L Nam, K L Winthrop, R F van Vollenhoven, et al.Lupus|December 6, 2012
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosusD J Wallace, S Navarra, M A Petri, et al.Annals of the Rheumatic Diseases|October 10, 2009
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesionsF Van den Bosch, B Manger, P Goupille, et al.Lupus|April 9, 2016
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosusL Kahl, J Patel, M Layton, et al.Annals of the Rheumatic Diseases|November 19, 2008
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialJ Smolen, R B Landewé, P Mease, et al.Scandinavian Journal of Rheumatology|September 28, 2018
Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaborationK Chatzidionysiou, G Lukina, C Gabay, et al.Clinical and Experimental Immunology|September 12, 2019
Dysregulated Fcγ receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patientsM Newling, R H Fiechter, L Sritharan, et al.Clinical and Experimental Rheumatology|February 18, 2014
The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational studyR Westhovens, R F van Vollenhoven, D T Boumpas, et al.Pageof 8